KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Net Cash Flow (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Net Cash Flow for 11 consecutive years, with $61.1 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 15.98% to $61.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $49.2 million through Dec 2025, up 153.91% year-over-year, with the annual reading at $49.2 million for FY2025, 153.91% up from the prior year.
  • Net Cash Flow hit $61.1 million in Q4 2025 for CRISPR Therapeutics AG, down from $92.9 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $521.8 million in Q2 2021 to a low of -$636.3 million in Q3 2021.
  • Historically, Net Cash Flow has averaged -$41.3 million across 5 years, with a median of -$42.1 million in 2021.
  • Biggest five-year swings in Net Cash Flow: crashed 695.46% in 2021 and later soared 3243.38% in 2023.
  • Year by year, Net Cash Flow stood at -$88.5 million in 2021, then crashed by 223.76% to -$286.4 million in 2022, then soared by 51.61% to -$138.6 million in 2023, then soared by 152.44% to $72.7 million in 2024, then fell by 15.98% to $61.1 million in 2025.
  • Business Quant data shows Net Cash Flow for CRSP at $61.1 million in Q4 2025, $92.9 million in Q3 2025, and -$41.6 million in Q2 2025.